-DOCSTART- -X- O
BACKGROUND. -X- _ O
Recent -X- _ O
trials -X- _ O
suggest -X- _ O
procalcitonin-based -X- _ O
guidelines -X- _ O
can -X- _ O
reduce -X- _ O
antibiotic -X- _ O
use -X- _ O
for -X- _ O
respiratory -X- _ O
infections. -X- _ O
However -X- _ O
, -X- _ O
the -X- _ O
accuracy -X- _ O
of -X- _ O
procalcitonin -X- _ B-Intervention
to -X- _ O
discriminate -X- _ O
between -X- _ O
viral -X- _ B-Patient
and -X- _ I-Patient
bacterial -X- _ I-Patient
pneumonia -X- _ I-Patient
requires -X- _ O
further -X- _ O
dissection. -X- _ O
METHODS. -X- _ O
We -X- _ O
evaluated -X- _ O
the -X- _ O
association -X- _ O
between -X- _ O
serum -X- _ B-Intervention
procalcitonin -X- _ I-Intervention
concentration -X- _ I-Intervention
at -X- _ O
hospital -X- _ O
admission -X- _ O
with -X- _ O
pathogens -X- _ O
detected -X- _ O
in -X- _ O
a -X- _ O
multicenter -X- _ O
prospective -X- _ O
surveillance -X- _ O
study -X- _ O
of -X- _ O
adults -X- _ B-Patient
hospitalized -X- _ I-Patient
with -X- _ I-Patient
community-acquired -X- _ I-Patient
pneumonia. -X- _ I-Patient
Systematic -X- _ O
pathogen -X- _ O
testing -X- _ O
included -X- _ O
cultures -X- _ O
, -X- _ O
serology -X- _ O
, -X- _ O
urine -X- _ O
antigen -X- _ O
tests -X- _ O
, -X- _ O
and -X- _ O
molecular -X- _ O
detection. -X- _ O
Accuracy -X- _ O
of -X- _ O
procalcitonin -X- _ B-Intervention
to -X- _ O
discriminate -X- _ B-Patient
between -X- _ I-Patient
viral -X- _ I-Patient
and -X- _ I-Patient
bacterial -X- _ I-Patient
pathogens -X- _ I-Patient
was -X- _ O
calculated. -X- _ O
RESULTS. -X- _ O
Among -X- _ B-Outcome
1735 -X- _ I-Outcome
patients -X- _ I-Outcome
, -X- _ I-Outcome
pathogens -X- _ I-Outcome
were -X- _ I-Outcome
identified -X- _ I-Outcome
in -X- _ I-Outcome
645 -X- _ I-Outcome
( -X- _ I-Outcome
37 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
including -X- _ I-Outcome
169 -X- _ I-Outcome
( -X- _ I-Outcome
10 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
with -X- _ I-Outcome
typical -X- _ I-Outcome
bacteria -X- _ I-Outcome
, -X- _ I-Outcome
67 -X- _ I-Outcome
( -X- _ I-Outcome
4 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
with -X- _ I-Outcome
atypical -X- _ I-Outcome
bacteria -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
409 -X- _ I-Outcome
( -X- _ I-Outcome
24 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
with -X- _ I-Outcome
viruses -X- _ I-Outcome
only. -X- _ I-Outcome
Median -X- _ I-Outcome
procalcitonin -X- _ I-Outcome
concentration -X- _ I-Outcome
was -X- _ I-Outcome
lower -X- _ I-Outcome
with -X- _ I-Outcome
viral -X- _ I-Outcome
pathogens -X- _ I-Outcome
( -X- _ I-Outcome
0.09 -X- _ I-Outcome
ng -X- _ I-Outcome
/ -X- _ I-Outcome
mL -X- _ I-Outcome
; -X- _ I-Outcome
interquartile -X- _ I-Outcome
range -X- _ I-Outcome
[ -X- _ I-Outcome
IQR -X- _ I-Outcome
] -X- _ I-Outcome
, -X- _ I-Outcome
< -X- _ I-Outcome
0.05–0.54 -X- _ I-Outcome
ng -X- _ I-Outcome
/ -X- _ I-Outcome
mL -X- _ I-Outcome
) -X- _ I-Outcome
than -X- _ I-Outcome
atypical -X- _ I-Outcome
bacteria -X- _ I-Outcome
( -X- _ I-Outcome
0.20 -X- _ I-Outcome
ng -X- _ I-Outcome
/ -X- _ I-Outcome
mL -X- _ I-Outcome
; -X- _ I-Outcome
IQR -X- _ I-Outcome
, -X- _ I-Outcome
< -X- _ I-Outcome
0.05–0.87 -X- _ I-Outcome
ng -X- _ I-Outcome
/ -X- _ I-Outcome
mL -X- _ I-Outcome
; -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.05 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
typical -X- _ I-Outcome
bacteria -X- _ I-Outcome
( -X- _ I-Outcome
2.5 -X- _ I-Outcome
ng -X- _ I-Outcome
/ -X- _ I-Outcome
mL -X- _ I-Outcome
; -X- _ I-Outcome
IQR -X- _ I-Outcome
, -X- _ I-Outcome
0.29–12.2 -X- _ I-Outcome
ng -X- _ I-Outcome
/ -X- _ I-Outcome
mL -X- _ I-Outcome
; -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
.01 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Procalcitonin -X- _ I-Outcome
discriminated -X- _ I-Outcome
bacterial -X- _ I-Outcome
pathogens -X- _ I-Outcome
, -X- _ I-Outcome
including -X- _ I-Outcome
typical -X- _ I-Outcome
and -X- _ I-Outcome
atypical -X- _ I-Outcome
bacteria -X- _ I-Outcome
, -X- _ I-Outcome
from -X- _ I-Outcome
viral -X- _ I-Outcome
pathogens -X- _ I-Outcome
with -X- _ I-Outcome
an -X- _ I-Outcome
area -X- _ I-Outcome
under -X- _ I-Outcome
the -X- _ I-Outcome
receiver -X- _ I-Outcome
operating -X- _ I-Outcome
characteristic -X- _ I-Outcome
( -X- _ I-Outcome
ROC -X- _ I-Outcome
) -X- _ I-Outcome
curve -X- _ I-Outcome
of -X- _ I-Outcome
0.73 -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
confidence -X- _ I-Outcome
interval -X- _ I-Outcome
[ -X- _ I-Outcome
CI -X- _ I-Outcome
] -X- _ I-Outcome
, -X- _ I-Outcome
.69–.77 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
A -X- _ I-Outcome
procalcitonin -X- _ I-Outcome
threshold -X- _ I-Outcome
of -X- _ I-Outcome
0.1 -X- _ I-Outcome
ng -X- _ I-Outcome
/ -X- _ I-Outcome
mL -X- _ I-Outcome
resulted -X- _ I-Outcome
in -X- _ I-Outcome
80.9 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
, -X- _ I-Outcome
75.3 -X- _ I-Outcome
% -X- _ I-Outcome
– -X- _ I-Outcome
85.7 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
sensitivity -X- _ I-Outcome
and -X- _ I-Outcome
51.6 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
, -X- _ I-Outcome
46.6 -X- _ I-Outcome
% -X- _ I-Outcome
–56.5 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
specificity -X- _ I-Outcome
for -X- _ I-Outcome
identification -X- _ I-Outcome
of -X- _ I-Outcome
any -X- _ I-Outcome
bacterial -X- _ I-Outcome
pathogen. -X- _ I-Outcome
Procalcitonin -X- _ I-Outcome
discriminated -X- _ I-Outcome
between -X- _ I-Outcome
typical -X- _ I-Outcome
bacteria -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
combined -X- _ I-Outcome
group -X- _ I-Outcome
of -X- _ I-Outcome
viruses -X- _ I-Outcome
and -X- _ I-Outcome
atypical -X- _ I-Outcome
bacteria -X- _ I-Outcome
with -X- _ I-Outcome
an -X- _ I-Outcome
area -X- _ I-Outcome
under -X- _ I-Outcome
the -X- _ I-Outcome
ROC -X- _ I-Outcome
curve -X- _ I-Outcome
of -X- _ I-Outcome
0.79 -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
, -X- _ I-Outcome
.75–.82 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
CONCLUSIONS. -X- _ O
No -X- _ B-Outcome
procalcitonin -X- _ I-Outcome
threshold -X- _ I-Outcome
perfectly -X- _ I-Outcome
discriminated -X- _ I-Outcome
between -X- _ I-Outcome
viral -X- _ I-Outcome
and -X- _ I-Outcome
bacterial -X- _ I-Outcome
pathogens -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
higher -X- _ I-Outcome
procalcitonin -X- _ I-Outcome
strongly -X- _ I-Outcome
correlated -X- _ I-Outcome
with -X- _ I-Outcome
increased -X- _ I-Outcome
probability -X- _ I-Outcome
of -X- _ I-Outcome
bacterial -X- _ I-Outcome
pathogens -X- _ I-Outcome
, -X- _ I-Outcome
particularly -X- _ I-Outcome
typical -X- _ I-Outcome
bacteria -X- _ I-Outcome
. -X- _ O

